{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:16:09Z","timestamp":1787019369803,"version":"build-2736575974"},"reference-count":64,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"Laboratorios Sophia, S.A. de C.V."}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therapeutic Advances in Drug Safety"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Bevacizumab, an anti-vascular endothelial growth factor agent initially approved for cancer treatment, is widely used off-label in retinal vascular diseases; however, this use may carry safety risks, particularly when evidence from controlled clinical trials is limited. In this context, real-world evidence derived from large pharmacovigilance databases plays a critical role in evaluating its safety profile.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>Evaluate the safety profile of off-label intravitreal bevacizumab for the treatment of retinal vascular diseases using the FDA Adverse Event Reporting System (FAERS) database.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design:<\/jats:title>\n                    <jats:p>Disproportionality analysis using data mining of the FAERS database.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Individual case safety reports (ICSRs) of intravitreal bevacizumab from Q1 2015 to Q2 2025 were extracted, and data mining methods (reporting odds ratio, proportional reporting ratio and Bayesian confidence propagation neural network) were applied to identify statistical disproportionality. In addition, a comparative risk analysis (odds ratio) was performed against ranibizumab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Of the 1495 ICSRs (5232 adverse events (AEs)), 114 preferred terms were statistically significant in the disproportionality analyses; 52% were expected, 15% were related to lack of efficacy and 33% were unexpected. Furthermore, the comparative analysis suggests a higher risk of serious cardiovascular, ocular and systemic events with ranibizumab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Most of the disproportionately reported AEs associated with bevacizumab were expected or related to product handling, underscoring the importance of using approved single-dose formulations. While this analysis suggests a lower risk of serious systemic AEs with bevacizumab than with ranibizumab, this finding should be interpreted with caution, as disproportionality analyses based on spontaneous reporting systems cannot confirm causal associations. Further evidence is needed to confirm the observed associations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/20420986261462682","type":"journal-article","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T12:15:16Z","timestamp":1785240916000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Disproportionality analysis of off-label intravitreal bevacizumab in the FDA Adverse Event Reporting System database"],"prefix":"10.1177","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9918-2024","authenticated-orcid":false,"given":"Homero","family":"Contreras-Salinas","sequence":"first","affiliation":[{"name":"Pharmacovigilance Department, Laboratorios Sophia, S.A. de C.V., Av. Paseo del Norte 5255, Zapopan, Jalisco 45010, M\u00e9xico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6686-0183","authenticated-orcid":false,"given":"Janet Cristina","family":"V\u00e1zquez-Beltr\u00e1n","sequence":"additional","affiliation":[{"name":"Pharmacovigilance Department, Laboratorios Sophia, S.A. de C.V., Zapopan, M\u00e9xico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3898-2148","authenticated-orcid":false,"given":"Gisela","family":"Garc\u00eda-S\u00e1nchez","sequence":"additional","affiliation":[{"name":"Regional Medical Affairs Department, Laboratorios Sophia, S.A. de C.V., Zapopan, M\u00e9xico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2730-4343","authenticated-orcid":false,"given":"Sebastian","family":"Quirarte-Justo","sequence":"additional","affiliation":[{"name":"Regional Medical Affairs Department, Laboratorios Sophia, S.A. de C.V., Zapopan, M\u00e9xico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-7892-2326","authenticated-orcid":false,"given":"Sarah\u00ed del Carmen","family":"G\u00f3mez-Mac\u00edas","sequence":"additional","affiliation":[{"name":"Regional Medical Affairs Department, Laboratorios Sophia, S.A. de C.V., Zapopan, M\u00e9xico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4424-4213","authenticated-orcid":false,"given":"Lourdes Yolotzin","family":"Rodr\u00edguez-Herrera","sequence":"additional","affiliation":[{"name":"Pharmacovigilance Department, Laboratorios Sophia, S.A. de C.V., Zapopan, M\u00e9xico"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,7,28]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S383101"},{"issue":"3","key":"e_1_3_4_3_2","article-title":"Anti-vascular endothelial growth factor for neovascular age-related macular degeneration","volume":"3","author":"Solomon SD","year":"2019","unstructured":"Solomon SD, Lindsley K, Vedula SS, et al. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration. Cochrane Database Syst Rev 2019; 3(3): CD005139.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2005.11.019"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.4103\/0301-4738.36474"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.3390\/ph16081140"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2019.09.024"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-025-04293-4"},{"key":"e_1_3_4_9_2","unstructured":"Roche. Core Data Sheet Avastin https:\/\/assets.roche.com\/f\/184741\/x\/63ad903c58\/avastin.pdf (2020 accessed 23 September 2025)."},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1102673"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.oftal.2014.09.011"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011230"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1590\/S1984-82502011000100006"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2015.6058"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2020.07.028"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2014.17"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.3701"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.7150\/ijms.6048"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1186\/1745-6215-13-138"},{"key":"e_1_3_4_20_2","doi-asserted-by":"crossref","unstructured":"Chamberlain C Kortepeter C Mu\u00f1oz M. Chapter 26 - Clinical analysis of adverse drug reactions and pharmacovigilance. In: Huang SM Lertora JJL Vicini P Atkinson AJBTAP of CP. Academic Press 2022 pp. 499\u2013517.","DOI":"10.1016\/B978-0-12-819869-8.00036-7"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1136\/medethics-2018-105286"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.4103\/IJO.IJO_2166_23"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.3390\/ph17081000"},{"key":"e_1_3_4_24_2","unstructured":"European Medicines Agency (EMA). Lytenava (bevacizumab) https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/lytenava (2025 accessed 13 November 2025)."},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-024-01421-9"},{"key":"e_1_3_4_26_2","unstructured":"Food and Drug Administration. FDA Adverse Event Reporting System (FAERS) Quarterly Data Extract Files. https:\/\/fis.fda.gov\/extensions\/FPD-QDE-FAERS\/FPD-QDE-FAERS.html (accessed 18 June 2025)."},{"key":"e_1_3_4_27_2","unstructured":"Barrett T Dowle M Srinivasan A et al. data.table: Extension of \u201cdata.frame\u201d. R package version 1.17.99. Published online 2025. https:\/\/r-datatable.com"},{"key":"e_1_3_4_28_2","unstructured":"Wickham H Fran\u00e7ois R Lionel H. dplyr: A Grammar of Data Manipulation. R package version 1.1.4. Published online 2025. https:\/\/dplyr.tidyverse.org"},{"key":"e_1_3_4_29_2","doi-asserted-by":"crossref","unstructured":"Wickham H. Ggplot2: Elegant Graphics for Data Analysis. Springer-Verlag New York; 2016. https:\/\/ggplot2.tidyverse.org","DOI":"10.1007\/978-3-319-24277-4_9"},{"key":"e_1_3_4_30_2","unstructured":"openxlsx2: Read Write and Edit \u201cxlsx\u201d Files. R package version 1.22. Published online 2025. https:\/\/janmarvin.github.io\/openxlsx2\/"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1038\/sdata.2016.26"},{"key":"e_1_3_4_32_2","unstructured":"Outlook Therapeutics Limited. Summary of Product Characteristics. Lytenava https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/lytenava-epar-product-information_en.pdf (2024 accessed 7 November 2025)."},{"key":"e_1_3_4_33_2","unstructured":"Council for International Organizations of Medical Sciences (CIOMS). Practical Aspects of Signal Detection in Pharmacovigilance- Report of CIOMS Working Group VIII. https:\/\/cioms.ch\/wp-content\/uploads\/2018\/03\/WG8-Signal-Detection.pdf (2010 accessed 10 November 2025)."},{"key":"e_1_3_4_34_2","unstructured":"European Medicines Agency. Screening for Adverse Reactions in EudraVigilance https:\/\/www.ema.europa.eu\/en\/documents\/other\/screening-adverse-reactions-eudravigilance_en.pdf (2016 accessed 21 November 2025)."},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1038\/eye.2013.107"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2015.35"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2011.11.035"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2014.3591"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2015.2556"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00347-024-01997-8"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.1111\/aos.15089"},{"key":"e_1_3_4_42_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-3768.2011.02240.x"},{"key":"e_1_3_4_43_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2014-305252"},{"key":"e_1_3_4_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60484-9"},{"key":"e_1_3_4_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.inat.2023.101746"},{"key":"e_1_3_4_46_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11906-013-0403-y"},{"key":"e_1_3_4_47_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-053698"},{"key":"e_1_3_4_48_2","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.959285"},{"key":"e_1_3_4_49_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-022-02325-x"},{"key":"e_1_3_4_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2015.06.017"},{"key":"e_1_3_4_51_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.113134"},{"issue":"6","key":"e_1_3_4_52_2","first-page":"444","article-title":"Correlation between extracutaneous microvascular complications and diabetic foot ulcers in patients with type 2 diabetes mellitus","volume":"74","author":"Balaban J","year":"2020","unstructured":"Balaban J, Bijelic R, Milicevic S, et al. Correlation between extracutaneous microvascular complications and diabetic foot ulcers in patients with type 2 diabetes mellitus. Med Arch (Sarajevo, Bosnia Herzegovina) 2020; 74(6): 444\u2013449.","journal-title":"Med Arch (Sarajevo, Bosnia Herzegovina)"},{"key":"e_1_3_4_53_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2011.01.004"},{"issue":"10","key":"e_1_3_4_54_2","first-page":"1","article-title":"The predictors of early treatment effectiveness of intravitreal bevacizumab application in patients with diabetic macular edema","volume":"14","author":"Kati\u0107 K","year":"2024","unstructured":"Kati\u0107 K, Kati\u0107 J, Kumri\u0107 M, et al. The predictors of early treatment effectiveness of intravitreal bevacizumab application in patients with diabetic macular edema. Diagnostics (Basel, Switzerland) 2024; 14(10): 1\u201313.","journal-title":"Diagnostics (Basel, Switzerland)"},{"key":"e_1_3_4_55_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-021-02121-2"},{"key":"e_1_3_4_56_2","doi-asserted-by":"publisher","DOI":"10.1210\/er.2018-00163"},{"key":"e_1_3_4_57_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2025.1653753"},{"key":"e_1_3_4_58_2","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines13061308"},{"key":"e_1_3_4_59_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11739-019-02253-7"},{"key":"e_1_3_4_60_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2013.02.034"},{"key":"e_1_3_4_61_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)61501-9"},{"issue":"10","key":"e_1_3_4_62_2","first-page":"1","article-title":"Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis","volume":"2018","author":"Virgili G","year":"2018","unstructured":"Virgili G, Parravano M, Evans JR, et al. Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis. Cochrane Database Syst Rev 2018; 2018(10): 1\u2013142.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_4_63_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-014-2886-x"},{"key":"e_1_3_4_64_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-007-0660-z"},{"key":"e_1_3_4_65_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2013.06.020"}],"container-title":["Therapeutic Advances in Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20420986261462682","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/20420986261462682","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20420986261462682","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T07:47:07Z","timestamp":1785484027000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/20420986261462682"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":64,"alternative-id":["10.1177\/20420986261462682"],"URL":"https:\/\/doi.org\/10.1177\/20420986261462682","relation":{},"ISSN":["2042-0986","2042-0994"],"issn-type":[{"value":"2042-0986","type":"print"},{"value":"2042-0994","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]},"article-number":"20420986261462682"}}